Cadila Pharmaceuticals on 21 November 2013 launched a new lung cancer drug, Mycidac-C, which is priced 40000 rupees for 10 course injection. The drug is much cheaper than the drugs manufactured by the multinational companies.
Cadila developed the drug after 15 years research and it will be available in Indian market from December 2013. Mycidac-C has been licensed and approved by the Drug Controller General of India (DCGI). The drug, Mycidac-C is meant for the patients, who suffer from non-small cell lung cancer (NSCLC).
If you have any Question/Point on the above information, please ask/discuss it in the Current Affairs Group
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.